• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

构建一种新工具,用于预测未接受手术的甲状腺乳头状癌患者的癌症特异性生存。

Construction of a new tool for predicting cancer-specific survival in papillary thyroid cancer patients who have not received surgery.

机构信息

Department of Pain, The First People's Hospital of Chenzhou, The First Affiliated Hospital of Xiangnan University, Chenzhou, Hunan, China.

School of Basic Medicine, Xiangnan University, Chenzhou, Hunan, China.

出版信息

Front Endocrinol (Lausanne). 2024 Aug 16;15:1417528. doi: 10.3389/fendo.2024.1417528. eCollection 2024.

DOI:10.3389/fendo.2024.1417528
PMID:39220367
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11361927/
Abstract

BACKGROUND

The prevalence of papillary thyroid cancer is gradually increasing and the trend of youthfulness is obvious. Some patients may not be able to undergo surgery, which is the mainstay of treatment, due to physical or financial reasons. Therefore, the prediction of cancer-specific survival (CSS) in patients with non-operated papillary thyroid cancer is necessary.

METHODS

Patients' demographic and clinical information was extracted from the Surveillance, Epidemiology, and End Results database. SPSS software was used to perform Cox regression analyses as well as propensity score matching analyses. R software was used to construct and validate the nomogram. X-tile software was used to select the best cutoff point for patient risk stratification.

RESULTS

A total of 1319 patients were included in this retrospective study. After Cox regression analysis, age, grade, T stage, M stage, radiotherapy, and chemotherapy were used to construct the nomogram. C-index, calibration curves, and receiver operating characteristic curves all verified the high predictive accuracy of the nomogram. The decision curve analysis demonstrated that patients could gain clinical benefit from this predictive model. Survival curve analysis after propensity score matching demonstrated the positive effects of radiotherapy on CSS in non-operated patients.

CONCLUSION

Our retrospective study successfully established a nomogram that accurately predicts CSS in patients with non-operated papillary thyroid cancer and demonstrated that radiotherapy for operated patients can still help improve prognosis. These findings can help clinicians make better choices.

摘要

背景

甲状腺乳头状癌的发病率逐渐升高,且呈现年轻化趋势。部分患者可能由于身体或经济原因无法接受手术这一主要治疗手段。因此,对未行手术的甲状腺乳头状癌患者进行癌症特异性生存(CSS)预测是必要的。

方法

从监测、流行病学和最终结果数据库中提取患者的人口统计学和临床信息。采用 SPSS 软件进行 Cox 回归分析和倾向评分匹配分析,使用 R 软件构建和验证列线图。使用 X-tile 软件选择患者风险分层的最佳截断值。

结果

本回顾性研究共纳入 1319 例患者。经 Cox 回归分析,年龄、分级、T 分期、M 分期、放疗和化疗被用于构建列线图。C 指数、校准曲线和受试者工作特征曲线均验证了该列线图的高预测准确性。决策曲线分析表明,该预测模型可以为患者带来临床获益。倾向评分匹配后生存曲线分析表明,放疗对未手术患者的 CSS 有积极影响。

结论

本回顾性研究成功建立了一个能够准确预测未手术甲状腺乳头状癌患者 CSS 的列线图,并表明放疗对手术患者仍有助于改善预后。这些发现有助于临床医生做出更好的选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93f6/11361927/f663bfe10280/fendo-15-1417528-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93f6/11361927/b1401dca1639/fendo-15-1417528-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93f6/11361927/a48c6ea7d587/fendo-15-1417528-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93f6/11361927/4f8d03158630/fendo-15-1417528-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93f6/11361927/fb04a79e2154/fendo-15-1417528-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93f6/11361927/0fcdcfb05e46/fendo-15-1417528-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93f6/11361927/f663bfe10280/fendo-15-1417528-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93f6/11361927/b1401dca1639/fendo-15-1417528-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93f6/11361927/a48c6ea7d587/fendo-15-1417528-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93f6/11361927/4f8d03158630/fendo-15-1417528-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93f6/11361927/fb04a79e2154/fendo-15-1417528-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93f6/11361927/0fcdcfb05e46/fendo-15-1417528-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93f6/11361927/f663bfe10280/fendo-15-1417528-g006.jpg

相似文献

1
Construction of a new tool for predicting cancer-specific survival in papillary thyroid cancer patients who have not received surgery.构建一种新工具,用于预测未接受手术的甲状腺乳头状癌患者的癌症特异性生存。
Front Endocrinol (Lausanne). 2024 Aug 16;15:1417528. doi: 10.3389/fendo.2024.1417528. eCollection 2024.
2
Development and validation of a nomogram to predict cancer-specific survival in elderly patients with papillary thyroid carcinoma: a population-based study.开发和验证一种列线图,用于预测老年甲状腺乳头状癌患者的癌症特异性生存:一项基于人群的研究。
BMC Geriatr. 2022 Sep 8;22(1):736. doi: 10.1186/s12877-022-03430-8.
3
Treatment strategies and predicting lymph node metastasis in elderly patients with papillary thyroid microcarcinoma.老年甲状腺微小乳头状癌患者的治疗策略及淋巴结转移预测
Medicine (Baltimore). 2021 May 7;100(18):e25811. doi: 10.1097/MD.0000000000025811.
4
Natural History and Prognostic Model of Untreated Papillary Thyroid Cancer: A SEER Database Analysis.未治疗的甲状腺乳头状癌的自然史和预后模型:SEER 数据库分析。
Cancer Control. 2024 Jan-Dec;31:10732748241253956. doi: 10.1177/10732748241253956.
5
Development of a novel dynamic nomogram for predicting overall survival in anaplastic thyroid cancer patients with distant metastasis: a population-based study based on the SEER database.基于 SEER 数据库的人群研究:开发一种新的预测伴远处转移的间变性甲状腺癌患者总生存的动态列线图
Front Endocrinol (Lausanne). 2024 Jul 4;15:1375176. doi: 10.3389/fendo.2024.1375176. eCollection 2024.
6
Clinical characteristics and prognostic nomogram for patients with insular thyroid carcinoma: a population-based analysis.甲状腺腺叶内癌患者的临床特征及预后列线图:一项基于人群的分析
Endocrine. 2023 Feb;79(2):331-341. doi: 10.1007/s12020-022-03200-x. Epub 2022 Oct 7.
7
Development and validation of survival nomograms for patients with differentiated thyroid cancer with distant metastases: a SEER Program-based study.基于 SEER 计划的研究:分化型甲状腺癌伴远处转移患者生存列线图的建立与验证。
J Endocrinol Invest. 2024 Jan;47(1):115-129. doi: 10.1007/s40618-023-02129-w. Epub 2023 Jun 9.
8
A nomogram and risk classification system for predicting cancer-specific survival in tall cell variant of papillary thyroid cancer: a SEER-based study.基于 SEER 数据库的高细胞型甲状腺乳头状癌癌特异性生存预测列线图和风险分级系统。
J Endocrinol Invest. 2023 May;46(5):893-901. doi: 10.1007/s40618-022-01949-6. Epub 2022 Nov 15.
9
Development and validation of a nomogram to predict overall survival in patients with redefined anaplastic thyroid carcinoma based on the SEER database.基于 SEER 数据库构建并验证预测重新定义的间变性甲状腺癌患者总生存的列线图。
Int J Clin Oncol. 2024 Jun;29(6):744-754. doi: 10.1007/s10147-024-02495-2. Epub 2024 Apr 7.
10
Competing risk nomogram and risk classification system for evaluating overall and cancer-specific survival in neuroendocrine carcinoma of the cervix: a population-based retrospective study.基于人群的回顾性研究:用于评估宫颈神经内分泌癌患者总生存和癌症特异性生存的竞争风险列线图和风险分类系统。
J Endocrinol Invest. 2024 Jun;47(6):1545-1557. doi: 10.1007/s40618-023-02261-7. Epub 2024 Jan 3.

本文引用的文献

1
The Incidence Trend and Management of Thyroid Cancer-What Has Changed in the Past Years: Own Experience and Literature Review.甲状腺癌的发病趋势与管理——过去几年有何变化:自身经验与文献综述
Cancers (Basel). 2023 Oct 11;15(20):4941. doi: 10.3390/cancers15204941.
2
A prediction nomogram for postoperative gastroparesis syndrome in right colon cancer: a retrospective study.右半结肠癌术后胃瘫综合征预测列线图:一项回顾性研究。
Langenbecks Arch Surg. 2023 Apr 13;408(1):148. doi: 10.1007/s00423-023-02885-6.
3
Thyroid cancer.甲状腺癌。
Lancet. 2023 May 6;401(10387):1531-1544. doi: 10.1016/S0140-6736(23)00020-X. Epub 2023 Apr 3.
4
A novel nomogram for predicting the decision to delayed extubation after thoracoscopic lung cancer surgery.一种预测胸腔镜肺癌手术后是否延迟拔管的新列线图。
Ann Med. 2023 Dec;55(1):800-807. doi: 10.1080/07853890.2022.2160490.
5
Evaluating Disease-specific Survival Prediction of Risk Stratification and TNM Systems in Differentiated Thyroid Cancer.评估分化型甲状腺癌中风险分层和 TNM 系统的疾病特异性生存预测。
J Clin Endocrinol Metab. 2023 May 17;108(6):e267-e274. doi: 10.1210/clinem/dgac721.
6
Radioiodine therapy in the different stages of differentiated thyroid cancer.分化型甲状腺癌不同阶段的放射性碘治疗
Best Pract Res Clin Endocrinol Metab. 2023 Jan;37(1):101703. doi: 10.1016/j.beem.2022.101703. Epub 2022 Sep 10.
7
ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer.欧洲肿瘤内科学会(ESMO)关于晚期甲状腺癌全身治疗应用的临床实践指南更新
Ann Oncol. 2022 Jul;33(7):674-684. doi: 10.1016/j.annonc.2022.04.009. Epub 2022 Apr 28.
8
Stereotactic radiotherapy (SRT) for differentiated thyroid cancer (DTC) oligometastases: an AIRO (Italian association of radiotherapy and clinical oncology) systematic review.立体定向放疗(SRT)治疗分化型甲状腺癌(DTC)寡转移灶:AIRO(意大利放射治疗和临床肿瘤学协会)的系统评价。
Radiol Med. 2022 Jun;127(6):681-689. doi: 10.1007/s11547-022-01489-2. Epub 2022 Apr 8.
9
The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020.全球甲状腺癌的流行病学概况:2020 年发病率和死亡率的 GLOBOCAN 估计。
Lancet Diabetes Endocrinol. 2022 Apr;10(4):264-272. doi: 10.1016/S2213-8587(22)00035-3. Epub 2022 Mar 7.
10
2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer.2021 年美国甲状腺协会甲状腺间变性癌患者管理指南。
Thyroid. 2021 Mar;31(3):337-386. doi: 10.1089/thy.2020.0944.